As radiopharmaceuticals advance toward regulatory approval and standard-of-care (SOC) designation, the demand for theranostic services is rapidly increasing. In response, the University Health Network (UHN), a major multi-site Canadian hospital system, has launched a strategic, interdisciplinary initiative to transition theranostics from clinical research to routine care. Guided by a multi-year implementation roadmap, UHN addresses critical elements such as infrastructure, reimbursement, capacity planning, fundraising, and governance. This approach draws on clinical trial expertise and industry partnerships to enable scalable, sustainable integration of theranostics into mainstream healthcare

• Key components of UHN’s multi-year roadmap for implementing theranostics as a standard of care
• Operational and systemic challenges in transitioning theranostics from research to routine clinical use
• The role of hospital–industry collaboration in scaling and sustaining a theranostics program